Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, Wunderlich M, O'Brien E, Perentesis JP, Starczynowski DT, Thomas CJ. Jones LM, et al. Among authors: hueneman k. J Clin Invest. 2020 Apr 1;130(4):2017-2023. doi: 10.1172/JCI127907. J Clin Invest. 2020. PMID: 32149729 Free PMC article.
TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis.
Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT. Fang J, et al. Among authors: hueneman km. Cell Rep. 2018 Jan 30;22(5):1250-1262. doi: 10.1016/j.celrep.2018.01.013. Cell Rep. 2018. PMID: 29386112 Free PMC article.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT. Melgar K, et al. Among authors: hueneman k. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828. doi: 10.1126/scitranslmed.aaw8828. Sci Transl Med. 2019. PMID: 31484791 Free PMC article.
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia.
Chlon TM, Stepanchick E, Hershberger CE, Daniels NJ, Hueneman KM, Kuenzi Davis A, Choi K, Zheng Y, Gurnari C, Haferlach T, Padgett RA, Maciejewski JP, Starczynowski DT. Chlon TM, et al. Among authors: hueneman km. Cell Stem Cell. 2021 Nov 4;28(11):1966-1981.e6. doi: 10.1016/j.stem.2021.08.004. Epub 2021 Sep 1. Cell Stem Cell. 2021. PMID: 34473945 Free PMC article.
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.
Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee LH, Greis KD, Vasyliev N, Khodadadi-Jamayran A, Nudler E, Lujambio A, Lowe SW, Aifantis I, Starczynowski DT. Muto T, et al. Among authors: hueneman k. Cell Stem Cell. 2022 Feb 3;29(2):298-314.e9. doi: 10.1016/j.stem.2021.12.007. Epub 2022 Jan 18. Cell Stem Cell. 2022. PMID: 35045331 Free PMC article.
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, Garrett-Bakelman FE, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmemmedov E, Seibel WL, Starczynowski DT. Barreyro L, et al. Among authors: hueneman km. Sci Transl Med. 2022 Mar 9;14(635):eabb7695. doi: 10.1126/scitranslmed.abb7695. Epub 2022 Mar 9. Sci Transl Med. 2022. PMID: 35263148
12 results